.Attributes Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of clients with HER2+ enhanced breast cancer and also energetic or even secure mind metastases revealed constant intracranial activity and also systemic efficacy of T-DXd.